130 related articles for article (PubMed ID: 22285028)
21. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
22. Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase.
Bagdanoff JT; Jain R; Han W; Zhu S; Madiera AM; Lee PS; Ma X; Poon D
Bioorg Med Chem Lett; 2015 Sep; 25(18):3788-92. PubMed ID: 26259804
[TBL] [Abstract][Full Text] [Related]
23. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.
Foloppe N; Fisher LM; Francis G; Howes R; Kierstan P; Potter A
Bioorg Med Chem; 2006 Mar; 14(6):1792-804. PubMed ID: 16289938
[TBL] [Abstract][Full Text] [Related]
24. (10
Lee SM; Kim NH; Lee S; Kim YN; Heo JD; Rho JR; Jeong EJ
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540496
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
Lainchbury M; Collins I
Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
[TBL] [Abstract][Full Text] [Related]
27. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
28. Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling.
Kani S; Nakayama E; Yoda A; Onishi N; Sougawa N; Hazaka Y; Umeda T; Takeda K; Ichijo H; Hamada Y; Minami Y
Genes Cells; 2007 Aug; 12(8):919-28. PubMed ID: 17663721
[TBL] [Abstract][Full Text] [Related]
29. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
30. Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett MD; Collins I
Trends Pharmacol Sci; 2011 May; 32(5):308-16. PubMed ID: 21458083
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of C-glycosyl pyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as a scaffold for check point kinase 1 inhibitors.
Ichikawa S; Tatebayashi N; Matsuda A
J Org Chem; 2013 Dec; 78(23):12065-75. PubMed ID: 24127858
[TBL] [Abstract][Full Text] [Related]
32. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Tanaka T; Ohgi T; Yano J
Genes Cells; 2005 Feb; 10(2):97-106. PubMed ID: 15676021
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of tricyclic cores for kinase inhibition.
Van Epps S; Fiamengo B; Edmunds J; Ericsson A; Frank K; Friedman M; George D; George J; Goedken E; Kotecki B; Martinez G; Merta P; Morytko M; Shekhar S; Skinner B; Stewart K; Voss J; Wallace G; Wang L; Wang L; Wishart N
Bioorg Med Chem Lett; 2013 Feb; 23(3):693-8. PubMed ID: 23265875
[TBL] [Abstract][Full Text] [Related]
34. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.
White AW; Carpenter N; Lottin JR; McClelland RA; Nicholson RI
Eur J Med Chem; 2012 Oct; 56():246-53. PubMed ID: 22995819
[TBL] [Abstract][Full Text] [Related]
36. Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
Katz JD; Haidle A; Childers KK; Zabierek AA; Jewell JP; Hou Y; Altman MD; Szewczak A; Chen D; Harsch A; Hayashi M; Warren L; Hutton M; Nuthall H; Su HP; Munshi S; Stanton MG; Davies IW; Munoz B; Northrup A
Bioorg Med Chem Lett; 2017 Jan; 27(1):114-120. PubMed ID: 27816515
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
Jobson AG; Cardellina JH; Scudiero D; Kondapaka S; Zhang H; Kim H; Shoemaker R; Pommier Y
Mol Pharmacol; 2007 Oct; 72(4):876-84. PubMed ID: 17616632
[TBL] [Abstract][Full Text] [Related]
38. Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.
Zhang N; Zhong R; Yan H; Jiang Y
Chem Biol Drug Des; 2011 Mar; 77(3):199-205. PubMed ID: 21244636
[TBL] [Abstract][Full Text] [Related]
39. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.
Deslandes S; Chassaing S; Delfourne E
Mar Drugs; 2009 Dec; 7(4):754-86. PubMed ID: 20098609
[TBL] [Abstract][Full Text] [Related]
40. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
